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Editorial
The present issue of Radiologia Brasileira presents an interesting article aimed
at offering radiologists an overview about magnetic resonance imaging (MRI) of the
prostate(1). MRI has been utilized since the early years of the eighties for the diagnosis
of prostate cancer. The first studies reported the identification of prostate cancer as
focal areas with hypointense signal on T2-weighted sequences. Even utilizing mid-
field or low-field equipment and body coils, a new, exciting and enthusiastic possi-
bility emerged as a noninvasive method for the diagnosis of prostate cancer and,
maybe, a new hope for men who could not endure the digital rectal examination and
biopsy…(2).
Already by the mid eighties, the zonal anatomy of the prostate could be better
demonstrated by high-field and high-gradient equipment. Most tumors were seen as
hypointense nodules in the peripheral zone that presents signal hyperintensity. Late
in the eighties, several investigators evaluated the possibility of local staging, despite
the utilization of body coils. Again, the results seemed to be amazing, or …optimis-
tic?… achieving 90% accuracy! However, in the nineties, the optimism turned into
disappointment with more realistic results demonstrating the low capacity of the
method for staging extracapsular invasion(2).
In 1986, the introduction of endorectal coils, in the University of Pennsylvania,
represented an effort to increase the local signal intensity and resulted in a great im-
provement in the spatial resolution. The optimism was back…(3).
From that moment on, the metabolic study of the prostate by spectroscopy could
be developed. The history repeated once again; the first enthusiastic results advocated
not only that was the issue regarding staging definitely resolved, but also that the
screening for cancer should be performed with MRI. Again, men could count on an
additional diagnostic imaging method in the propedeutic arsenal. This method was
immediately accepted by the urologists and included in the routine imaging proto-
cols.
The MRI and spectroscopy accuracy is “radiologist’-dependent. Many centers
have compared and still compare surgical findings with the radiological evaluation
in an attempt to audit their own services. The learning curve is relatively long and
depends on the training of the radiologist.
The signal patterns of adenocarcinoma, hyperplasia and prostatitis still may
overlap each other, but several study groups have demonstrated that there are sig-
nificant metabolic differences allowing their differentiation; therefore, combined MRI
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and spectroscopy increases the method accuracy. However, the utilization of this
method is still restricted to reference institutions(4).
Screening for prostate cancer represents a problem completely different from a
loco-regional evaluation of a known neoplasm. This method must provide a cancer or
non-cancer diagnosis with high sensitivity and high specificity. Additionally, the
method must differentiate cancer from prostatitis and hyperplasia, besides the typi-
cal variations(5–7).
Also, for a prospective evaluation of the spectroscopy clinical utility, it is neces-
sary to understand the rationale of how the metaboloma, in the genomic and proteomic
era, offers a potentially powerful tool. One can simply consider metabolites as a final
product of proteomic and genomic alterations. Furthermore, with the advantage that
metabolites constitute the obvious path/steps of the ubiquitous cellular processes.
Diffusion and perfusion imaging are also added to spectroscopy in the functional
evaluation of the prostate, with similar history and results.
Despite this spectrum of possibilities, we are still confronted with comments
such as “I´m tired of reading articles with exaggerated false promises.”.
Even with the current limitations, in the future we will certainly be able to offer
a golden-standard-like method for the diagnosis of prostate cancer!!!
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